143 related articles for article (PubMed ID: 29909520)
1. Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer.
Guo XF; Li SS; Zhu XF; Dou QH; Liu D
Cancer Chemother Pharmacol; 2018 Sep; 82(3):383-394. PubMed ID: 29909520
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Ishiguro Y; Kimura M; Fujita K; Sakakibara A; Takahashi H; Toth G; Matsuda H
Oncol Rep; 2010 Apr; 23(4):957-63. PubMed ID: 20204279
[TBL] [Abstract][Full Text] [Related]
5. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
8. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
9. Dual Inhibition of EGFR and IGF-1R Signaling Leads to Enhanced Antitumor Efficacy against Esophageal Squamous Cancer.
Kang J; Guo Z; Zhang H; Guo R; Zhu X; Guo X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142299
[TBL] [Abstract][Full Text] [Related]
10. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
[TBL] [Abstract][Full Text] [Related]
11. MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.
Liu T; Guan F; Wang Y; Zhang Z; Li Y; Cui Y; Li Z; Liu H; Zhang Y; Wang Y; Ma S
Toxicol Appl Pharmacol; 2020 May; 395():114971. PubMed ID: 32217144
[TBL] [Abstract][Full Text] [Related]
12. Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
Meng RY; Jin H; Nguyen TV; Chai OH; Park BH; Kim SM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768915
[TBL] [Abstract][Full Text] [Related]
13. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.
Mu Y; Sun D
Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265
[TBL] [Abstract][Full Text] [Related]
15. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
16. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
17. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
18. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
20. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
